We are live on ! Find out more
UFF

USA Financial Formulas Portfolio holdings

AUM $531M
1-Year Est. Return 28.6%
This Fund
S&P 500
This Quarter Est. Return
+11.66%
1 Year Est. Return
+28.6%
3 Year Est. Return
+77.97%
5 Year Est. Return
10 Year Est. Return
AUM
$572M
AUM Growth
+$505M
Cap. Flow
+$466M
Cap. Flow %
81.59%
Top 10 Hldgs %
75.29%
Holding
570
New
76
Increased
157
Reduced
78
Closed
237

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.22M
2
BIIB icon
Biogen
BIIB
+$2.09M
3
GILD icon
Gilead Sciences
GILD
+$2.04M
4
ROST icon
Ross Stores
ROST
+$1.53M
5
MNST icon
Monster Beverage
MNST
+$1.53M

Sector Composition

Rank Sector Weight
1 Technology 7.26%
2 Industrials 3.12%
3 Communication Services 2.93%
4 Financials 2.5%
5 Consumer Discretionary 2.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UNP icon
201
Union Pacific
UNP
$176B
$44K 0.01%
179
+123
+220% +$27K
MET icon
202
MetLife
MET
$61.9B
$41.7K 0.01%
631
+591
+1,478% +$37K
CMI icon
203
Cummins
CMI
$89.7B
$41.4K 0.01%
173
-3,701
-96% -$841K
MRK icon
204
Merck
MRK
$317B
$41.4K 0.01%
380
-8,991
-96% -$933K
AAPL icon
205
Apple
AAPL
$4.54T
$41K 0.01%
213
-1,753
-89% -$324K
RTX icon
206
RTX Corp
RTX
$300B
$40.1K 0.01%
476
+398
+510% +$31.5K
NTES icon
207
NetEase
NTES
$82B
$37.4K 0.01%
401
+369
+1,153% +$39.2K
CSCO icon
208
Cisco
CSCO
$479B
$34.2K 0.01%
677
-3,358
-83% -$172K
STRL icon
209
Sterling Infrastructure
STRL
$16.4B
$31.7K 0.01%
361
-3,117
-90% -$225K
MHO icon
210
M/I Homes
MHO
$3.81B
$29.9K 0.01%
217
+185
+578% +$18.5K
CVS icon
211
CVS Health
CVS
$126B
$29.8K 0.01%
377
+321
+573% +$22.8K
BZH icon
212
Beazer Homes USA
BZH
$931M
$29K 0.01%
858
+841
+4,947% +$23K
MOD icon
213
Modine Manufacturing
MOD
$10.3B
$28.1K ﹤0.01%
470
-2,701
-85% -$132K
SCS
214
DELISTED
Steelcase
SCS
$27.6K ﹤0.01%
+2,042
New +$24.2K
ADI icon
215
Analog Devices
ADI
$184B
$27.6K ﹤0.01%
139
+65
+88% +$11.6K
HLNE icon
216
Hamilton Lane
HLNE
$5.56B
$27.6K ﹤0.01%
+243
New +$23K
BCC icon
217
Boise Cascade
BCC
$2.98B
$26.6K ﹤0.01%
206
+202
+5,050% +$21.7K
STNE icon
218
StoneCo
STNE
$2.72B
$26.4K ﹤0.01%
+1,466
New +$19.3K
MATX icon
219
Matsons
MATX
$6.22B
$26.2K ﹤0.01%
+239
New +$22.7K
AROC icon
220
Archrock
AROC
$5.95B
$26.1K ﹤0.01%
1,696
+1,659
+4,484% +$23.1K
FSS icon
221
Federal Signal
FSS
$7.95B
$26.1K ﹤0.01%
340
-1,043
-75% -$69.5K
AMAT icon
222
Applied Materials
AMAT
$424B
$25.9K ﹤0.01%
160
-2,383
-94% -$350K
NMIH icon
223
NMI Holdings
NMIH
$3.38B
$25.6K ﹤0.01%
861
-2,614
-75% -$73K
HNI icon
224
HNI Corp
HNI
$3.5B
$25.3K ﹤0.01%
+604
New +$23K
PFSI icon
225
PennyMac Financial
PFSI
$3.94B
$25.2K ﹤0.01%
+285
New +$21.4K

Similar funds

USA Financial Formulas's Q4 2023 Portfolio in Review

As of Q4 2023, USA Financial Formulas held 570 positions worth $572M, up 754% from $66.9M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

USA Financial Formulas deployed $466M of net new capital in Q4 2023, opening 76 new positions and adding to 157 existing holdings. Its largest new stake was iShares S&P 500 Growth ETF: 855,439 shares worth $64.2M.

By sector, the portfolio is most concentrated in Technology at 7.3% of assets, down from 17% a quarter earlier, followed by Industrials and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $2.09M trimmed.

  • USA Financial Formulas's largest Q4 2023 buy was iShares S&P 500 Growth ETF: 855,439 shares worth $64.2M.
  • USA Financial Formulas added most to iShares S&P Mid-Cap 400 Growth ETF in Q4 2023, an estimated $61.8M increase.
  • USA Financial Formulas's biggest Q4 2023 reduction was Biogen, cutting an estimated $2.09M.
  • USA Financial Formulas fully exited Regeneron Pharmaceuticals in Q4 2023, selling an estimated $2.22M.
  • USA Financial Formulas's ten largest holdings make up 75% of its $572M portfolio in Q4 2023.
  • USA Financial Formulas opened 76 new positions and closed 237 in Q4 2023.
  • USA Financial Formulas's portfolio value rose 754% quarter-over-quarter to $572M.

Based on USA Financial Formulas's 13F filing for Q4 2023, filed 7 Feb 2024.